Department of Medicine and Life Sciences, Hasselt University, Diepenbeek, Belgium.
Department of Cardiology, Ziekenhuis Oost-Limburg, Genk, Belgium.
Acta Cardiol. 2021 Jun;76(4):353-358. doi: 10.1080/00015385.2020.1736762. Epub 2020 Mar 6.
The impact of revascularisation of chronic total occlusions (CTO) on the incidence of ventricular arrhythmias (VA) remains to be elucidated.
Based on prospectively gathered data, the recurrence rate of VAs following CTO treatment was retrospectively investigated. Patients presenting with VAs as clinical indication for CTO revascularisation were retrospectively selected out of three Belgian CTO registries (i.e. Ziekenhuis Oost-Limburg, UZ Leuven and CHR de la Citadelle). Freedom of VAs was defined as absence of non-sustained or sustained tachycardias (VT), ventricular fibrillations (Vfib) and ventricular extrasystoles (VES; <2500 VES/24 h). Long-term outcome in terms of reoccurrence of VAs was evaluated by reviewing patient records.
Between 2011 and 2019, 912 patients underwent a CTO-PCI across three Belgian centres. In total 43 patients (5%) presented with VAs as clinical indication for CTO revascularisation. Overall follow-up was 723 (391 - 1144) days. Fourteen (33%), 18 (42%), 5 (11%) and 6 (14%) presented with >2500 VES/24 hrs, non-sustained VT, sustained VT and Vfib, respectively. In those patients with a one-year follow-up available ( = 34), overall recurrence rate of VAs was 38% (within VA group: VES: 25%, non-sustained VT: 46%; sustained VT: 25% and Vfib: 60%).
Based on this retrospective data analysis, CTO revascularisation, in patients presenting with VAs as the main clinical indication, seems to beneficially impact the incidence of VAs, which ultimately might result in improved patients' outcome.
血运重建慢性完全闭塞病变(CTO)对室性心律失常(VA)发生率的影响仍需阐明。
基于前瞻性收集的数据,回顾性调查了 CTO 治疗后 VA 的复发率。从三个比利时 CTO 登记处(即林堡大学医院、鲁汶大学医院和列日 citadelle 医院)中回顾性选择因 VA 作为 CTO 血运重建的主要临床指征而出现 VA 的患者。VA 无复发定义为无非持续性或持续性心动过速(VT)、心室颤动(Vfib)和室性期前收缩(VES;<2500VES/24 小时)。通过查阅患者记录评估 VA 再发的长期预后。
2011 年至 2019 年期间,三个比利时中心共对 912 例患者进行了 CTO-PCI。共有 43 例(5%)患者因 VA 作为 CTO 血运重建的主要临床指征而出现 VA。总的随访时间为 723(391-1144)天。14 例(33%)、18 例(42%)、5 例(11%)和 6 例(14%)分别表现为>2500VES/24 小时、非持续性 VT、持续性 VT 和 Vfib。在有一年随访的 34 例患者中,VA 的总体复发率为 38%(VA 组内:VES:25%,非持续性 VT:46%;持续性 VT:25%和 Vfib:60%)。
基于这项回顾性数据分析,CTO 血运重建对因 VA 作为主要临床指征而出现 VA 的患者的 VA 发生率有有益影响,这最终可能会改善患者的预后。